MedPath

Effects of Grape Powder on Psychological Distress and Gut Microbiota in College Students

Not Applicable
Recruiting
Conditions
Gut Microbiota
Psychological Distress
Registration Number
NCT07214428
Lead Sponsor
Rutgers, The State University of New Jersey
Brief Summary

The goal of this trial is to investigate the effect of freeze-dried table grape powder (FTGP) on psychological distress and gut microbiota in college students. The main questions it aims to answer are:

Does FTGP reduce anxiety, depression, and perceived stress? Does FTGP improve the gut microbiota? Researchers will compare FTGP to a placebo to see how FTGP affects psychological distress and gut microbiota.

Participants will:

Drink a daily supplement containing FTGP or a placebo for 4 weeks. Record consumption of grape powder or placebo in a compliance log. Complete surveys and provide stool samples. Three in-person visits.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Aged 18-30 years old
  • Able to give written informed consent.
  • BMI 18.5-24.9 kg/m2
  • Healthy (self-reported)
  • Can read and speak English
Exclusion Criteria
  • Currently taking medications that interfere with polyphenol
  • Currently using or have used antibiotics continuously for >3 days within 3 months prior to enrollment
  • Have had surgery involving the intestinal lumen within the last 30 days
  • Have a documented diagnosis of celiac disease or/and inflammatory bowel diseases
  • Are pregnant or breastfeeding
  • Have prediabetes and diabetes
  • Have had bariatric surgery
  • Are immunocompromised ( e.g., cancer treatment, bone marrow/organ transplant, immune deficiency, or poorly controlled HIV/AIDS)
  • Are unable to provide consent
  • Are hospitalized,
  • Have a history of or current alcohol, drug, or medication abuse (self-reported),
  • Have contraindication to any substance in the investigational product or who are currently enrolled in other interventional trials

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Hamilton Anxiety Scale -14baseline (1st), week 4 (2nd) and week 5 (3rd)

HAMA-14 is one of the earliest and most widely used clinical scales for measuring the severity of a patient's anxiety. It has 14 items, each reflecting a cluster of anxiety symptoms. Total range: 0 to 56, with higher scores indicating greater severity of anxiety

17-item of Hamilton Depression Rating Scalebaseline (1st), week 4 (2nd) and week5 (3rd)

HAMD-17 is one of the most widely used clinician-administered scales for measuring the severity of a patient's depression. It has 17 items, each covering symptoms of depression across mood, physical, and cognitive domains. With higher scores indicating greater severity of depression.

10-item of Perceived Stress Scalebaseline (1st), week 4 (2nd) and week5 (3rd)

PSS-10 is one of the most widely used psychological instruments for measuring the perception of stress. It has 10 items, each reflecting how unpredictable, uncontrollable, and overloaded respondents find their lives during the past month. Total range: 0 to 40, with higher scores indicating greater perceived stress.

Secondary Outcome Measures
NameTimeMethod
Shannon Index of gut microbiotabaseline (1st), week 4 (2nd) and week5 (3rd)

Changes in gut microbiota will be assessed from stool samples using 16S rRNA gene sequencing. Alpha diversity will be calculated using Shannon Index. This measure will characterize whether the intervention alters gut microbial diversity in each subject.

Beta diversity of gut microbiotabaseline (1st), week 4 (2nd) and week 5 (3rd)

Changes in gut microbiota will be assessed from stool samples using 16S rRNA gene sequencing. Beta diversity will be calculated using Bray Curtis distance between samples. This measure will characterize whether and how the intervention alters gut microbial communities.

fecal short chain fatty acidbaseline (1st), week 4 (2nd) and week5 (3rd)

fecal short chain fatty acid will be measured by GC-MS

Trial Locations

Locations (1)

Department of Biochemistry and Microbiology, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey

🇺🇸

New Brunswick, New Jersey, United States

Department of Biochemistry and Microbiology, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Shreya Ghosh
Contact
908-538-6896
ghosh.shreya@rutgers.edu

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.